Milestone Taking Etripamil Into Phase III For AFib Based On Phase II Success

Approval For PSVT Pending At The US FDA

The company’s calcium channel blocker nasal spray rapidly slowed atrial fibrillation patients’ heart rates, showing potential to be an at-home replacement for emergency room-administered treatment.

Atrial fibrillation medical condition and normal or abnormal heart rate rhythm as a cardiac disorder
Etripamil rapidly slowed ventricular rates in atrial fibrillation patients • Source: Shutterstock

Milestone Pharmaceuticals, Inc.’s inhaled calcium channel blocker etripamil already has shown that it can significantly slow patients’ heart rates in a large Phase III clinical trial as a treatment for paroxysmal supraventricular tachycardia (PSVT). Now, the company plans to initiate a Phase III trial in patients with atrial fibrillation with rapid ventricular rate (AFib-RVR) after the drug was similarly effective at lowering heart rate in the Phase II ReVeRA study of AFib-RVR patients.

Key Takeaways
  • Milestone reported positive Phase II results for its calcium channel blocker etripamil, administered via nasal spray, as a treatment for atrial fibrillation with rapid ventricular rate...

Montreal and Charlotte, NC-based Milestone submitted a new drug application for etripamil in the treatment of PSVT to the US Food and Drug Administration in October based on positive results...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By 

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.

More from R&D

Roivant Staying ‘Patient’ On Deals, Leaving Investors Waiting

 

CEO Matt Gline talked to Scrip in an interview about dealmaking and the road back to commercialization.

Bayer Has BI In Its Sights With Priority Review For HER2 Lung Cancer Drug

 
• By 

Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.

InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial

 
• By 

A study of the German biotech's intravenous complement factor C5a antibody for pyoderma gangrenosum was stopped for futility.